Cargando…

Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy

BACKGROUND: Studies on PD-L1 expression in breast cancer have gained importance in recent years, especially in triple-negative breast cancer (TNBC). Our aim was to analyze the differential expression of PD-L1 to explore its correlation with response to neoadjuvant chemotherapy (NACT) and patient sur...

Descripción completa

Detalles Bibliográficos
Autores principales: Oner, Gizem, Önder, Semen, Karatay, Hüseyin, Ak, Naziye, Tükenmez, Mustafa, Müslümanoğlu, Mahmut, İğci, Abdullah, Dincçağ, Ahmet, Özmen, Vahit, Aydiner, Adnan, Yavuz, Ekrem, Cabioğlu, Neslihan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8414710/
https://www.ncbi.nlm.nih.gov/pubmed/34474671
http://dx.doi.org/10.1186/s12957-021-02361-9
_version_ 1783747834269401088
author Oner, Gizem
Önder, Semen
Karatay, Hüseyin
Ak, Naziye
Tükenmez, Mustafa
Müslümanoğlu, Mahmut
İğci, Abdullah
Dincçağ, Ahmet
Özmen, Vahit
Aydiner, Adnan
Yavuz, Ekrem
Cabioğlu, Neslihan
author_facet Oner, Gizem
Önder, Semen
Karatay, Hüseyin
Ak, Naziye
Tükenmez, Mustafa
Müslümanoğlu, Mahmut
İğci, Abdullah
Dincçağ, Ahmet
Özmen, Vahit
Aydiner, Adnan
Yavuz, Ekrem
Cabioğlu, Neslihan
author_sort Oner, Gizem
collection PubMed
description BACKGROUND: Studies on PD-L1 expression in breast cancer have gained importance in recent years, especially in triple-negative breast cancer (TNBC). Our aim was to analyze the differential expression of PD-L1 to explore its correlation with response to neoadjuvant chemotherapy (NACT) and patient survival. METHODS: PD-L1 expression was evaluated immunohistochemically (Ventana SP263 clone kit) by staining tumor specimen. PD-L1 positivity was defined as membranous staining > 1%, > 5%, > 10%, and > 20% on either tumor cell (TC) and /or immune cell (IC). RESULTS: Fifty patients with locally advanced TNBC, who had a partial response to NACT, were included in the study. PD-L1 staining was observed in TCs in 25 patients (50%) and in ICs in 23 patients (46%) when PD-L1 > 1% was considered positive. Patients with PD-L1 positivity on ICs were more likely to respond to chemotherapy as measured by “MD Anderson Cancer Center Residual Cancer Burden Index” (14/22, 63.6% vs. 10/27, 37%, p = 0.064). The 5-year disease-free survival (DFS) and disease-specific survival (DSS) rates were 46.3% and 51.4%, respectively. A high (> 20%) tumoral PD-L1 positivity was associated with a better DFS and DSS. CONCLUSIONS: Studies in the literature mostly focused on PD-L1 expression in inflammatory cells. However, our results suggest that patients with a high PD-L1 expression on TCs were more likely to have a better outcome. Since patients with residual tumor burden who express PD-L1 on TILs were more likely to respond to NACT, an immune checkpoint inhibitor therapy in addition to NACT would be an important option for TNBC with locally advanced disease.
format Online
Article
Text
id pubmed-8414710
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-84147102021-09-09 Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy Oner, Gizem Önder, Semen Karatay, Hüseyin Ak, Naziye Tükenmez, Mustafa Müslümanoğlu, Mahmut İğci, Abdullah Dincçağ, Ahmet Özmen, Vahit Aydiner, Adnan Yavuz, Ekrem Cabioğlu, Neslihan World J Surg Oncol Research BACKGROUND: Studies on PD-L1 expression in breast cancer have gained importance in recent years, especially in triple-negative breast cancer (TNBC). Our aim was to analyze the differential expression of PD-L1 to explore its correlation with response to neoadjuvant chemotherapy (NACT) and patient survival. METHODS: PD-L1 expression was evaluated immunohistochemically (Ventana SP263 clone kit) by staining tumor specimen. PD-L1 positivity was defined as membranous staining > 1%, > 5%, > 10%, and > 20% on either tumor cell (TC) and /or immune cell (IC). RESULTS: Fifty patients with locally advanced TNBC, who had a partial response to NACT, were included in the study. PD-L1 staining was observed in TCs in 25 patients (50%) and in ICs in 23 patients (46%) when PD-L1 > 1% was considered positive. Patients with PD-L1 positivity on ICs were more likely to respond to chemotherapy as measured by “MD Anderson Cancer Center Residual Cancer Burden Index” (14/22, 63.6% vs. 10/27, 37%, p = 0.064). The 5-year disease-free survival (DFS) and disease-specific survival (DSS) rates were 46.3% and 51.4%, respectively. A high (> 20%) tumoral PD-L1 positivity was associated with a better DFS and DSS. CONCLUSIONS: Studies in the literature mostly focused on PD-L1 expression in inflammatory cells. However, our results suggest that patients with a high PD-L1 expression on TCs were more likely to have a better outcome. Since patients with residual tumor burden who express PD-L1 on TILs were more likely to respond to NACT, an immune checkpoint inhibitor therapy in addition to NACT would be an important option for TNBC with locally advanced disease. BioMed Central 2021-09-02 /pmc/articles/PMC8414710/ /pubmed/34474671 http://dx.doi.org/10.1186/s12957-021-02361-9 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Oner, Gizem
Önder, Semen
Karatay, Hüseyin
Ak, Naziye
Tükenmez, Mustafa
Müslümanoğlu, Mahmut
İğci, Abdullah
Dincçağ, Ahmet
Özmen, Vahit
Aydiner, Adnan
Yavuz, Ekrem
Cabioğlu, Neslihan
Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy
title Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy
title_full Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy
title_fullStr Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy
title_full_unstemmed Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy
title_short Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy
title_sort clinical impact of pd-l1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8414710/
https://www.ncbi.nlm.nih.gov/pubmed/34474671
http://dx.doi.org/10.1186/s12957-021-02361-9
work_keys_str_mv AT onergizem clinicalimpactofpdl1expressionintriplenegativebreastcancerpatientswithresidualtumorburdenafterneoadjuvantchemotherapy
AT ondersemen clinicalimpactofpdl1expressionintriplenegativebreastcancerpatientswithresidualtumorburdenafterneoadjuvantchemotherapy
AT karatayhuseyin clinicalimpactofpdl1expressionintriplenegativebreastcancerpatientswithresidualtumorburdenafterneoadjuvantchemotherapy
AT aknaziye clinicalimpactofpdl1expressionintriplenegativebreastcancerpatientswithresidualtumorburdenafterneoadjuvantchemotherapy
AT tukenmezmustafa clinicalimpactofpdl1expressionintriplenegativebreastcancerpatientswithresidualtumorburdenafterneoadjuvantchemotherapy
AT muslumanoglumahmut clinicalimpactofpdl1expressionintriplenegativebreastcancerpatientswithresidualtumorburdenafterneoadjuvantchemotherapy
AT igciabdullah clinicalimpactofpdl1expressionintriplenegativebreastcancerpatientswithresidualtumorburdenafterneoadjuvantchemotherapy
AT dinccagahmet clinicalimpactofpdl1expressionintriplenegativebreastcancerpatientswithresidualtumorburdenafterneoadjuvantchemotherapy
AT ozmenvahit clinicalimpactofpdl1expressionintriplenegativebreastcancerpatientswithresidualtumorburdenafterneoadjuvantchemotherapy
AT aydineradnan clinicalimpactofpdl1expressionintriplenegativebreastcancerpatientswithresidualtumorburdenafterneoadjuvantchemotherapy
AT yavuzekrem clinicalimpactofpdl1expressionintriplenegativebreastcancerpatientswithresidualtumorburdenafterneoadjuvantchemotherapy
AT cabiogluneslihan clinicalimpactofpdl1expressionintriplenegativebreastcancerpatientswithresidualtumorburdenafterneoadjuvantchemotherapy